Best percentage change from baseline. Of the 25 patients included in the primary efficacy analysis, 22 patients had lesions measurable after baseline and are included. Four patients had PR. GU, genitourinary; Gyn, gynecologic; PD, progressive disease; PR, partial response; SD, stable disease.